Clinical Trial Update: A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a fixed-dose combination inhaler FF/UMEC/VI to FF/VI in inadequately controlled asthma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol)
• FF/VI (fluticasone furoate/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2020-02-21